Skip to main content
. 2022 Nov 4;141(5):534–549. doi: 10.1182/blood.2022018221

Table 1.

Patient characteristics

Variables DDX41-WT DDX41-mutated Total
n (%) 8736 (96.2%) 346 (3.8%) 9082 (100%)
 Sporadic 8730 302 9032
 Familial (proband) 6 (6) 44 (36) 50 (42)
Age (median, range) 65, 1-94 68, 15-94 65, 1-94
Sex (male/female/unknown) 3666/2324/2746 274/72/0 3940/2396/2746
OS
 n of informative cases 2159 201 2360
 Median observation, range 1.2 y, 0-40.4 1.3 y, 0-22.7 1.2 y, 0-40.4
Leukemic progression
 n of informative cases 2128 174 2302
 Median observation, range 1.6 y, 0.01-32.3 1.7 y, 0.03-22.7 1.6 y, 0.01-32.3
Diagnosis
 MDS 4146 201 4347
 AML 2704 136 2840
 MDS/MPN 658 8 666
 MPN 1228 1 1229
Country
 Japan 4289 172 4461
 United States 1767 105 1872
 United Kingdom 1669 36 1705
 Italy 240 13 253
 Thailand 67 6 73
 The Netherlands 36 2 38
 Germany 668 12 680
Status at sampling
 At diagnosis 6961 275 7236
 Before treatment 430 32 462
 After treatment 877 39 916
 Unknown 468 0 468
Germ line DNA (%)
 Available 1003 (20.4%) 36 (20.9%) 1039 (23.3%)
 Not available 3286 (79.6%) 136 (79.1%) 3422 (76.7%)
Treatment
 Hypomethylating agents (HMA) 771 108 879
 Transplantation 1424 94 1518
 Chemotherapy 927 73 1000

Number of Japanese cases.